Polymorphism in the macrophage migration inhibitory factor (MIF) gene as marker for prostate cancer
AssigneeDepartment of Veterans Affairs
InventorsKatherine Siegler, Kenneth Iczkowski, Richard Bucala, Pedro L. Vera
Life of this patent
Estimating the term…
Abstract
The present invention relates to the risk assessment, detection, diagnosis, or prognosis of prostate cancer. More specifically, this invention relates to the detection of certain polymorphism in the promoter region of the MIF gene to determine the risk, detect, diagnose, or prognosticate prostate cancer. Applicants have discovered that the presence of a −173C and/or −749 (CATT)7 or more repeat predispose an individual to prostate cancer.
Claims5
A method for determining the risk of, detecting, diagnosing, or prognosticating prostate cancer in an individual, comprising the steps of testing the individual for the presence of a −173 C mutation or a CATT repeat in the promoter of the macrophage migration inhibitory factor (MIF) gene, wherein the CATT repeat is 7 or higher repeats locating at position −749, and wherein the testing step comprises
- a) collecting a nucleic acid sample from the individual;
- b) amplifying the nucleic acid sample;
- and
- c) sequencing the promoter of the MIF gene.
Dependencies are inferred from the claim text.